OOIR: Observatory of International Research

Papers

(The H4-Index of Experimental Hematology & Oncology is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
Prospective pharmacotyping of urothelial carcinoma organoids for drug sensitivity prediction – feasibility and real world experience	185
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities	163
Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity	156
Cardiotoxicity of small-molecule kinase inhibitors in cancer therapy	135
The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives	134
Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies	106
cGAS-ISG15-RAGE axis reprogram necroptotic microenvironment and promote lymphatic metastasis in head and neck cancer	100
Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux	78
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis	77
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics	74
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling	71
A correlation of ineffective erythropoiesis and dysregulated signaling pathways in myelodysplastic syndromes/neoplasms	69
Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside	69
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD	68
MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting	68
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review	67
HIV associated lymphoma: latest updates from 2023 ASH annual meeting	61
Targeting hepcidin in colorectal cancer triggers a TNF-dependent-gasdermin E-driven immunogenic cell death response	61
Correction: Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers	61
Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma	58
Multi-omic profiling of the leukemic microenvironment shows bone marrow interstitial fluid is distinct from peripheral blood plasma	56
Correction: Breast cancer heterogeneity and its implication in personalized precision therapy	53
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone	53
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	51
Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors	50

Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy	49
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways	47
Role of m6A writers, erasers and readers in cancer	47
Enhanced cellular therapy: revolutionizing adoptive cellular therapy	46
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies	45
Breast cancer heterogeneity and its implication in personalized precision therapy	44
Three-dimensional chromatin landscapes in MLLr AML	42
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells	42
Single-cell transcriptome analysis reveals stem cell-like subsets in the progression of Waldenström’s macroglobulinemia	41
Hetrombopag plus porcine ATG and cyclosporine for the treatment of aplastic anaemia: early outcomes of a prospective pilot study	41
Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting	40
IL-39 promotes chronic graft-versus-host disease by increasing T and B Cell pathogenicity	39
CD19/CD22 CAR-T-cell cocktail therapy following autologous transplantation is an optimizing strategy for treating relapsed/refractory central nervous system lymphoma	39
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	38
Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma	38